MBD2 deficiency does not accelerate p53 mediated lymphomagenesis.
Recent studies using hypomorphic DNA methyltransferase 1 (DNMT1) alleles have suggested that strategies aiming to reduce DNA methylation may increase genomic instability and lymphomagenesis. Given our recent finding that loss of methyl-binding domain protein 2 (Mbd2) suppresses intestinal tumorigenesis, we have tested whether loss of Mbd2 increases lymphomagenesis by intercrossing Mbd2 deficient mice with p53 deficient and p53 heterozygous mice. Unlike DNMT1, loss of Mbd2 does not accelerate lymphomagenesis, arguing that MBD2 may represent a better potential therapeutic target than DNMT1.
Sansom
Owen James
OJ
Mammalian Genetics, Cardiff School of Biosciences, University of Cardiff, Museum Avenue, PO Box 911, Cardiff CF10 3US, UK.
Bishop
Stefan Mark
SM
Bird
Adrian
A
Clarke
Alan Richard
AR
D000818:Animals; D019175:DNA Methylation; D004268:DNA-Binding Proteins / Q000235:genetics*; D008223:Lymphoma / Q000235:genetics / Q000473:pathology*; D051379:Mice; D018345:Mice, Knockout; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000502:physiology*
D004268:DNA-Binding Proteins; C115368:MBD2 protein; D016159:Tumor Suppressor Protein p53